Alex Biese

A recent study found that healthy tissue near the sites of lung tumors may contain genetic information that could serve as a predictor of possible cancer recurrence.

Dr. Nabil Rizk, chief of thoracic surgery at Hackensack University Medical Center, explains that segmentectomy is “just a little bit more of a refined way of treating cancers.”

Diane Messick, a three-time lung cancer survivor, tells CURE® about her cancer journey which has included a segmentectomy, a lobectomy and radiation treatment since receiving her first diagnosis in 2017.

As part of its Speaking Out® video series, CURE® spoke Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, about education disparities among patients with lung cancer.

As part of its Speaking Out® video series, CURE® spoke Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, about advancements in treating non-small cell lung cancer and the unmet needs that persist for patients.

As part of its Speaking Out® video series, CURE® spoke with Dusty Joy Donaldson of LiveLung/The Dusty Joy Foundation and Lung Cancer Action Network about her lung cancer journey and the importance of scans.

As part of its Speaking Out® video series, CURE® spoke with Kimberly Buchmeier, a lung cancer survivor and board member of LiveLung.

Findings of MANIFEST-2 show “valuable evidence that the addition of pelabresib offers meaningful improvements over JAK inhibitor monotherapy as a first-line approach for patients with myelofibrosis,” according to one expert.

Last week brought three more FDA approvals in the oncology space, as well as some research in neuropathy prevention and the diabetes-cancer connection.

Immune checkpoint inhibitors and stereotactic radiosurgery do not increase the risk of necrosis among patients with NSCLC who have brain metastases, according to research.

Truqap (capivasertib) with fulvestrant has been approved for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, the FDA announced.

A decade after becoming a bone marrow donor following his brother’s diagnosis of myelofibrosis, former “Queer Eye for the Straight Guy” co-star Thom Filicia is one of the partners behind the Mapping Myelofibrosis initiative.

Patients with colorectal cancer who had diabetes with complications had an 85% higher risk of death than those without diabetes, according to the findings of a study.

Last week’s oncology headlines focused on veterans with cancer, as well as FDA regulatory decisions and an expert’s opinion on what patients need to consider when choosing a Medicare plan.

Researchers found that some caregivers face racism and discrimination as they care for loved ones with cancer.

Up to a quarter of patients with breast cancer face financial burden due to the cost of supplements, complimentary therapy and alternative medicines which “may decrease adherence to prescribed medications,” researchers found.

U.S. Army Reserve Veteran and stage 3 colon cancer survivor discussed the significance of the 2022 passage of the PACT Act and what it means for veterans facing cancer.

Patients with metastatic colorectal cancer are eligible for treatment with Fruzaqla, an oral targeted therapy, following treatment via fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy as well as an anti-VEGF therapy, and, if their disease RAS wild-type and medically appropriate, an anti-EGFR therapy.

Dr. Gene G. Finley spoke about current patient treatment obstacles as part of CURE’s ‘Speaking Out’ video series.

Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.

U.S. veterans face exposures during military service and disparities at home.

Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival.

Checking PSA levels following treatment is crucial among patients with nonmetastatic, unfavorable risk prostate cancer, according to the co-author of a recent study.

CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.

Charlene Wexler, the Chicago-based author of the Laughter and Tears series of novels, is an ovarian cancer survivor who now has skin cancer. She told CURE® about how her son’s death from leukemia led to her re-invention as a writer.

Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until PSA recurrence and failure.

Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free survival.

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Amanda Smith, a registered nurse with Huntsman Cancer Institute, explained the impact early satiety can have on patients with MPNs and why communication with their care team is important.

According to the Food and Drug Administration, the shortage of Novartis’ prostate cancer treatment Pluvicto, which began in March, has been resolved, with the manufacturer expecting a continued expansion of supply.